Open AccessIntracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study
Author(s) -
Jenna Yager,
José CastilloMancilla,
Mustafa Ibrahim,
Kristina M Brooks,
Cricket McHugh,
Mary Morrow,
Scott McCallister,
Lane R. Bushman,
Samantha MaWhinney,
Jennifer J. Kiser,
Peter L. Anderson
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002354
Subject(s) - emtricitabine , tenofovir alafenamide , medicine , dosing , confidence interval , pre exposure prophylaxis , crossover study , urology , pharmacology , placebo , human immunodeficiency virus (hiv) , viral load , virology , men who have sex with men , pathology , alternative medicine , syphilis , antiretroviral therapy
Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States. The objective of this study was to assess the relationship between tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in dried blood spots (DBS) with adherence to TAF/FTC.